Izdanje Srbija
Serbische Ausgabe
Izdanje BiH
Izdanje Crna Gora
News
Source:
eKapija |
Thursday,
06.11.2025.|
11:15
LinkedIn
Email
Copy linkCompany founded by Serbs in America named best biotech startup for 2025 – Dren Bio developing cancer treatment therapies
Dren Bio, a privately held, clinical-stage biotechnology company developing therapeutics for cancer, autoimmune, and other serious diseases, has received the 2025 Prix Galien USA Award for “Best Biotech Startup” by the Galien Foundation. Dren Bio was founded in 2019 by Serbian scientists Nenad Tomasevic and Ivan Trifunovic. Ivan Trifunovic was appointed Ambassador of Serbia to Switzerland this year.
The Prix Galien USA Awards, as said in the company’s press release, honor excellence in leading-edge scientific innovation and are widely regarded as the most prestigious distinction in biopharmaceutical research and development. The 2025 award recognizes Dren Bio’s pioneering work in harnessing the body’s immune mechanisms to precisely and safely eliminate pathogenic cells.
The company was awarded for its technologies, including its autoreactive T-cell depleter (DR-01) and proprietary Targeted Myeloid Engager and Phagocytosis platform, which embody novel, highly differentiated approaches to selectively deplete disease-causing agents.
– Together, they exemplify the company’s mission to translate cutting-edge immunobiology into transformative therapies for cancer and autoimmune diseases – the press release says.
The Prix Galien USA judging committee brings together some of the most respected and accomplished figures in global biopharma, including Kenneth C. Frazier, Committee Chair, Former Chairman & CEO Merck, Roch Doliveux, Honorary CEO, UCB, Dr. Mikael Dolsten, Former CSO & President, Pfizer Research and Development, Alex Gorsky, Former CEO & Executive Chairman, Johnson & Johnson, Penny Heaton, Global Therapeutic Area Head, Vaccines, Janssen, Sheri McCoy, Board of Directors, AstraZeneca; Former CEO, Avon, Joel S. Marcus, Executive Chairman & Founder, Alexandria, and Elias Zerhouni, Former Head of Global R&D, Sanofi.
– We’re deeply honored by this recognition from such an esteemed jury. It reflects the strength of our science, the dedication of our team, and the potential of our programs to address high unmet need in both oncology and autoimmune diseases through a truly differentiated approach – said Nenad Tomasevic, Ph.D., Chief Executive Officer and Founder of Dren Bio.
By the way, in March this year, Dren Bio sold the drug DR-0201, which has proven effective in treating malignant diseases, to one of the world’s largest pharmaceutical companies, Sanofi, for up to USD 1.9 billion.
The Prix Galien USA Awards, as said in the company’s press release, honor excellence in leading-edge scientific innovation and are widely regarded as the most prestigious distinction in biopharmaceutical research and development. The 2025 award recognizes Dren Bio’s pioneering work in harnessing the body’s immune mechanisms to precisely and safely eliminate pathogenic cells.
The company was awarded for its technologies, including its autoreactive T-cell depleter (DR-01) and proprietary Targeted Myeloid Engager and Phagocytosis platform, which embody novel, highly differentiated approaches to selectively deplete disease-causing agents.
– Together, they exemplify the company’s mission to translate cutting-edge immunobiology into transformative therapies for cancer and autoimmune diseases – the press release says.
The Prix Galien USA judging committee brings together some of the most respected and accomplished figures in global biopharma, including Kenneth C. Frazier, Committee Chair, Former Chairman & CEO Merck, Roch Doliveux, Honorary CEO, UCB, Dr. Mikael Dolsten, Former CSO & President, Pfizer Research and Development, Alex Gorsky, Former CEO & Executive Chairman, Johnson & Johnson, Penny Heaton, Global Therapeutic Area Head, Vaccines, Janssen, Sheri McCoy, Board of Directors, AstraZeneca; Former CEO, Avon, Joel S. Marcus, Executive Chairman & Founder, Alexandria, and Elias Zerhouni, Former Head of Global R&D, Sanofi.
– We’re deeply honored by this recognition from such an esteemed jury. It reflects the strength of our science, the dedication of our team, and the potential of our programs to address high unmet need in both oncology and autoimmune diseases through a truly differentiated approach – said Nenad Tomasevic, Ph.D., Chief Executive Officer and Founder of Dren Bio.
By the way, in March this year, Dren Bio sold the drug DR-0201, which has proven effective in treating malignant diseases, to one of the world’s largest pharmaceutical companies, Sanofi, for up to USD 1.9 billion.
Only logged-in users can comment.
